RxDoctor Payments DataLook up a doctor →

Eleanya Ogburu-Ogbonnaya, MD

Neurology · Columbia, SCNPI 1104005941

Payments from drug & device makers

$136,647in general payments, 2019–2025

Across 692 payments — averaging $197.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$61K
  • Lexicon Pharmaceuticals, Inc.$25K
  • AbbVie$21K
  • Indivior Inc.$12K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • plus $13K from 54 others

What the payments were for

  • Speaking & faculty fees$19,09053%
  • Travel & lodging$4,37212%
  • Food & beverage$12,53135%
  • Education$2321%
  • Gifts$00%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck5$60,804
Lexicon Pharmaceuticals, Inc.6$25,293
AbbVie(2 entities)107$21,193
Indivior Inc.8$12,472
E.r. Squibb & Sons, L.L.C.2$1,924
Teva Pharmaceuticals USA, Inc.72$1,527
Flowonix Medical Incorporated2$1,372
Livanova USA, Inc.7$1,356
Abbott17$1,356
Forte Bio-pharma LLC41$1,150
Collegium Pharmaceutical, Inc.42$687
Neurocrine Biosciences, Inc.29$609
Eisai Inc.34$587
Pfizer36$556
AstraZeneca(2 entities)16$446
Scilex Pharmaceuticals Inc.28$384
Supernus Pharmaceuticals, Inc.31$334
Amgen10$291
Biohaven Pharmaceutical Holding Company Ltd.12$285
Lundbeck LLC9$250
Biohaven Pharmaceuticals, Inc.13$235
Amneal Pharmaceuticals LLC13$234
EMD Serono, Inc.12$223
Electronic Waveform Lab, Inc.3$219
Protega Pharmaceutials Inc12$219
MDD US Operations, LLC3$213
Alnylam Pharmaceuticals Inc.9$203
Zavation Medical Products, LLC1$189
Acadia Pharmaceuticals Inc7$131
Novo Nordisk7$131
Catalyst Pharmaceuticals, Inc.5$116
Braeburn Inc.6$115
Virtus Pharmaceuticals LLC7$108
Akcea Therapeutics, Inc.5$104
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$93
Impel Pharmaceuticals Inc.5$92
Johnson & Johnson5$90
Neurelis, Inc.5$86
Axsome Therapeutics, Inc.4$79
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$77
Grifols USA, LLC4$69
Novartis4$68
Upsher-smith Laboratories LLC3$59
Sunovion Pharmaceuticals Inc.3$56
Hikma Pharmaceuticals USA3$53
Arbor Pharmaceuticals, Inc.3$44
Bausch Health US, LLC2$42
Kaleo, Inc.3$36
Hospira, Inc.2$36
Bristol Myers Squibb2$33
Ultragenyx Pharmaceutical Inc.1$25
Otsuka America Pharmaceutical, Inc.1$24
Avanir Pharmaceuticals, Inc.2$24
Sanofi1$24
USWM, LLC1$24
Merz Pharmaceuticals, LLC1$22
Alkermes, Inc.1$19
Azurity Pharmaceuticals, Inc.1$19
Jazz Pharmaceuticals Inc.1$18
Greenwich Biosciences, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$136,647 in reported general payments places this provider in the 90th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$336,547
Medicare patients
259
Services billed
9,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate633$337,598
OxycontinOxycodone Hcl321$196,757
Nurtec OdtRimegepant Sulfate106$189,518
Austedo XrDeutetrabenazine29$181,120
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen2,673$173,882
OzempicSemaglutide163$160,863
LinzessLinaclotide264$157,278
IngrezzaValbenazine Tosylate17$146,013
CopaxoneGlatiramer Acetate18$99,050
MounjaroTirzepatide70$71,920
VraylarCariprazine Hcl48$70,674
UbrelvyUbrogepant50$64,355
Dimethyl Fumarate33$56,580
ProlateOxycodone Hcl/Acetaminophen17$41,805
TrulancePlecanatide60$36,819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er$687$357,170646 claims
AbbVieLinzess, Vraylar, Ubrelvy, Botox, Qulipta$21,193$333,556396 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr, Copaxone$1,527$280,17047 claims
PfizerNurtec Odt$556$189,518106 claims
Novo NordiskOzempic, Rybelsus$131$177,380180 claims
Neurocrine Biosciences, Inc.Ingrezza$609$146,01317 claims
Forte Bio-pharma LLCProlate$1,150$41,80517 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$77$36,81960 claims
Scilex Pharmaceuticals Inc.Ztlido$384$27,73850 claims
Eisai Inc.Fycompa$587$25,31524 claims
Amneal Pharmaceuticals LLCRytary$234$13,12421 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$53$9,57284 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 270 neurology providers in South Carolina.

Other neurology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →